Thioguanine pharmacokinetics in induction therapy of children with acute myeloid leukemia

Anti-Cancer Drugs

Volumn 20, Issue 1, 2009, Pages 7-14

  Josefine, Palle ^a,b   Britt Marie, Frost ^a,b   Curt, Petersson ^a,c   Henrik, Hasle ^a,d   Marit, Hellebostad ^a,f   Jukka, Kanerva ^a,g   Kjeld, Schmiegelow ^a,e   Gudmar, Lönnerholm ^a  

^a On Behalf of the Nordic Society for Paediatric Haematology and Oncology

^b UNIVERSITY CHILDREN S HOSPITAL   (Sweden)

^c LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^d AARHUS UNIVERSITY   (Denmark)

^e University of Copenhagen   (Denmark)

^f ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^g UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Acute myeloid leukemia; Childhood; Pharmacokinetics; Thioguanine

Indexed keywords

CYTARABINE; DOXORUBICIN; ETOPOSIDE; HEMOGLOBIN; METHOTREXATE; TIOGUANINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CHILD; CLINICAL ARTICLE; DOWN SYNDROME; DRUG BLOOD LEVEL; DRUG ERYTHROCYTE LEVEL; DRUG MEGADOSE; DRUG MONITORING; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD;

EID: 57349184592     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32831bc086     Document Type: Article

References (29)

1. Coulthard S, Hogarth L The thiopurines: an update. Invest New Drugs 2005; 23:523-532.
2. Adamson PC, Poplack DG, Balis FM. The cytotoxicity of thioguanine vs mercaptopurine in acute lymphoblastic leukemia. Leuk Res 1994; 18: 805-810.
3. Lennard L, Keen D, Lilleyman JS. Oral 6-mercaptopurine in childhood leukemia: parent drug pharmacokinetics and active metabolite concentrations. Clin Pharmacol Ther 1986; 40:287-292.
4. Erb N, Harms DO, Janka-Schaub G. Pharmacokinetics and metabolism of thiopurines in children with acute lymphoblastic leukemia receiving 6-thioguanine versus 6-mercaptopurine. Cancer Chemother Pharmacol 1998; 42:266-272.
5. Harms DO, Gobel U, Spaar HJ, Graubner UB, Jorch N, Gutjahr P, et al. Thioguanine offers no advantage over mercaptopurine in maintenance treatment of childhood ALL: results of the randomized trial COALL-92. Blood 2003; 102:2736-2740.
6. Jacobs SS, Stork LC, Bostrom BC, Hutchinson R, Holcenberg J, Reaman GH, et al. Substitution of oral and intravenous thioguanine for mercaptopurine in a treatment regimen for children with standard risk acute lymphoblastic leukemia: a collaborative Children's Oncology Group/National Cancer Institute pilot trial (CCG-1942). Pediatr Blood Cancer 2007; 49:250-255.
7. Vora A, Mitchell CD, Lennard L, Eden TO, Kinsey SE, Lilleyman J, et al. Toxicity and efficacy of 6-thioguanine versus 6-mercaptopurine in childhood lymphoblastic leukaemia: a randomised trial. Lancet 2006; 368:1339-1348.
8. McCormack J, Johns D. Purine and purine nucleoside antimetabolites. In: Chabner BW, Collins JM, editors. Cancer chemotherapy; principles and practice. Philadelphia: J.B. Lippincott; 1990, pp. 234-250.
9. Lie SO, Abrahamsson J, Clausen N, Forestier E, Hasle H, Hovi L, et al. Longterm results in children with AML: NOPHO-AML Study Group-report of three consecutive trials. Leukemia 2005; 19:2090-2100.
10. Zimm S, Collins JM, Riccardi R, O'Neill D, Narang PK, Chabner B, et al. Variable bioavailability of oral mercaptopurine. Is maintenance chemotherapy in acute lymphoblastic leukemia being optimally delivered? N Engl J Med 1983; 308:1005-1009.
11. Brox LW, Birkett L, Belch A. Clinical pharmacology of oral thioguanine in acute myelogenous leukemia. Cancer Chemother Pharmacol 1981; 6:35-38.
12. Lennard L, Lilleyman JS. Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia. J Clin Oncol 1989; 7:1816-1823.
13. Schmiegelow K, Bruunshuus I. 6 Thioguanine nucleotide accumulation in red blood cells during maintenance chemotherapy for childhood acute lymphoblastic leukemia, and its relation to leukopenia. Cancer Chemother Pharmacol 1990; 26:288-292.
14. Sulh H, Koren G, Whalen C, Soldin S, Zipursky A, Greenberg M. Pharmacokinetic determinants of 6-mercaptopurine myelotoxicity and therapeutic failure in children with acute lymphoblastic leukemia. Clin Pharmacol Ther 1986; 40:604-609.
15. Abildgaard L, Ellebaek E, Gustafsson G, Abrahamsson J, Hovi L, Jonmundsson G, et al. Optimal treatment intensity in children with Down syndrome and myeloid leukaemia: data from 56 children treated on NOPHO-AML protocols and a review of the literature. Ann Hematol 2006; 85:275-280.
16. Lie SO, Abrahamsson J, Clausen N, Forestier E, Hasle H, Hovi L, et al. Treatment stratification based on initial in vivo response in acute myeloid leukaemia in children without Down's syndrome: results of NOPHO-AML trials. Br J Haematol 2003; 122:217-225.
17. Lennard L, Singleton HJ. High-performance liquid chromatographic assay of the methyl and nucleotide metabolites of 6-mercaptopurine: quantitation of red blood cell 6-thioguanine nucleotide, 6-thioinosinic acid and 6-methylmercaptopurine metabolites in a single sample. J Chromatogr 1992; 583:83-90.
18. Palle J, Frost BM, Peterson C, Gustafsson G, Hellebostad M, Kanerva J, et al. Doxorubicin pharmacokinetics is correlated to the effect of induction therapy in children with acute myeloid leukemia. Anticancer Drugs 2006; 17:385-392.
19. Palle J, Britt-Marie F, Goran G, Marit H, Jukka K, Eva L, et al. Etoposide pharmacokinetics in children treated for acute myeloid leukemia. Anticancer Drugs 2006; 17:1087-1094.
20. Lancaster DL, Patel N, Lennard L, Lilleyman JS. 6-Thioguanine in children with acute lymphoblastic leukaemia: influence of food on parent drug pharmacokinetics and 6-thioguanine nucleotide concentrations. Br J Clin Pharmacol 2001; 51:531-539.
21. Lennard L, Davies HA, Lilleyman JS. Is 6-thioguanine more appropriate than 6-mercaptopurine for children with acute lymphoblastic leukaemia? Br J Cancer 1993; 68:186-190.
22. Balis FM, Holcenberg JS, Poplack DG, Ge J, Sather HN, Murphy RF, et al. Pharmacokinetics and pharmacodynamics of oral methotrexate and mercaptopurine in children with lower risk acute lymphoblastic leukemia: a joint children's cancer group and pediatric oncology branch study. Blood 1998; 92:3569-3577.
23. Creutzig U, Reinhardt D, Diekamp S, Dworzak M, Stary J, Zimmermann M. AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity. Leukemia 2005; 19:1355-1360.
24. Craze JL, Harrison G, Wheatley K, Hann IM, Chessells JM. Improved outcome of acute myeloid leukaemia in Down's syndrome. Arch Dis Child 1999; 81:32-37.
25. Ravindranath Y, Abella E, Krischer JP, Wiley J, Inoue S, Harris M, et al. Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: experience on Pediatric Oncology Group AML Study 8498. Blood 1992; 80:2210-2214.
26. Zeller B, Gustafsson G, Forestier E, Abrahamsson J, Clausen N, Heldrup J, et al. Acute leukaemia in children with Down syndrome: a population-based Nordic study. Br J Haematol 2005; 128:797-804.
27. Lancaster DL, Lennard L, Rowland K, Vora AJ, Lilleyman JS. Thioguanine versus mercaptopurine for therapy of childhood lymphoblastic leukaemia: a comparison of haematological toxicity and drug metabolite concentrations. Br J Haematol 1998; 102:439-443.
28. Lancaster DL, Patel N, Lennard L, Lilleyman JS. Leucocyte versus erythrocyte thioguanine nucleotide concentrations in children taking thiopurines for acute lymphoblastic leukaemia. Cancer Chemother Pharmacol 2002; 50:33-36.
29. Bergan S, Bentdal O, Sodal G, Brun A, Rugstad HE, Stokke O. Patterns of azathioprine metabolites in neutrophils, lymphocytes, reticulocytes, and erythrocytes: relevance to toxicity and monitoring in recipients of renal allografts. Ther Drug Monit 1997; 19:502-509.